# Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292

> **NCT01692184** · PHASE1 · COMPLETED · sponsor: **Celgene** · enrollment: 54 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** 50 mg AVL-292
- **DRUG:** 100 mg AVL-292
- **DRUG:** 200 mg AVL-292
- **DRUG:** 350 mg AVL-292
- **DRUG:** Placebo capsules

## Key facts

- **NCT ID:** NCT01692184
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-01
- **Primary completion:** 2012-10-08
- **Final completion:** 2012-10-08
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01692184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01692184, "Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01692184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*